Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
暂无分享,去创建一个
C. Leborgne | S. Boutin | O. Benveniste | P. Véron | C. Masurier | V. Monteilhet | M. Montus | Virginie Monteilhet